All In Biotech

Drug Trial Radar · NCT07166211

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With CSU

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 27, 2025

Primary completion

Nov 2, 2026

Study completion Jan 14, 2027

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.

Conditions

  • Chronic Spontaneous Urticaria (CSU)

Interventions

  • CM512 injectionBiological

    subcutaneous injection

  • placeboDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from the baseline in 7-day urticaria activity score (UAS7) at 16 weeks of treatment (W16)Time frame: Up to 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Academy of Traditional Chinese Medicine Affiliate Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.